Royalty Pharma plc

RPRX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$57.17-2.16%

2026-08-03

Financials

Valuation Metrics

Royalty Pharma plc's Market Cap is $32.92B. At end of 2025 it was $16.69B. Ranked #425 of 3,111 in US market (top 14%), #125 of 1,445 on NASDAQ (top 9%), #21 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$32.92B	US#425/3,111 Sec#21/269
Revenue	$2.44B	US#1,368/3,111 Sec#38/269
Net Income	$828M	US#606/3,111 Sec#24/269
Total Assets	$19.82B	US#620/3,111 Sec#23/269
Net Assets	$6.89B	US#565/3,111 Sec#23/269
Value
P/E	39.78x	US#1,730/3,111 Sec#56/269
P/B	4.78x	US#2,173/3,111 Sec#139/269
PEG	1.67x	US#989/3,111 Sec#34/269
P/S	13.49x	US#2,745/3,111 Sec#132/269
EV/EBITDA	24.31x	US#2,055/3,111 Sec#62/269
FCF Yield	8.06%	US#761/3,111 Sec#27/269
Profitability
ROE	12.01%	US#1,124/3,111 Sec#54/269
ROA	4.18%	US#1,156/3,111 Sec#58/269
Op. Margin	67.93%	US#40/3,111 Sec#2/269
Revenue Growth	10.97%	US#1,232/3,111 Sec#91/269
Earnings Growth	23.77%	US#839/3,111 Sec#34/269
Financial Health
Debt Ratio	143.41%	US#1,450/3,111 Sec#187/269
Total Debt	$8.96B	US#436/3,111 Sec#21/269
FCF	$2.65B	US#280/3,111 Sec#17/269
Cash	$586M	US#978/3,111 Sec#50/269
Current Ratio	2.66x	US#932/3,111 Sec#205/269
Net Debt/EBITDA	4.93x	US#2,033/3,111 Sec#83/269
Dividend
Div. Yield	1.18%	US#1,242/3,111 Sec#19/269
Div. Growth	0.47%	US#1,184/3,111 Sec#21/269
Performance
1Y Return	54.06%	US#589/3,111 Sec#111/269
1M Return	-1.04%	US#919/3,111 Sec#58/269
From 52W High	-5.41%	US#321/3,111 Sec#16/269
1Y MDD	-7.94%	US#22/3,111 Sec#1/269
Trading
Volume	2,570,061 shares	US#825/3,111 Sec#68/269
Trading Value	$148M	US#786/3,111 Sec#44/269
Per Share
EPS	$1.79	US#1,347/3,111 Sec#46/269
BPS	$15.00	US#1,482/3,111 Sec#47/269